Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 582

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1B
Chunk 582
---
 loss expense- loan
    due from related party 
     130,000  
     - 
  
    Loss on extinguishment
    of debt 
     -  
     7,486,767 
  
    Amortization of debt issuance
    costs 
     4,338,543  
     1,611,458 
  
    Change in operating assets
    and liabilities: 

    Trade accounts payable
    and accrued expenses 
     183,629  
     114,556 
  
    Prepaid
    expenses 
     (57,160) 
     (713)
  
    Net
    cash used in operating activities 
    $(5,070,428) 
    $(3,859,796)

    Cash Flows from Financing
    activities 

    Payment of deferred offering
    costs 
     -  
     (255,970)
  
    Payments under related
    party line of credit 
     (101,000) 
     - 
  
    Proceeds from (payments
    to) due to/from related party 
     (433,945) 
     1,663,164 
  
    Borrowings under related
    party line of credit 
     -  
     1,452,414 
  
    Proceeds from warrant exercises 
     37,300  
     - 
  
    Proceeds
    from sale of common stock 
     6,832,973  
     1,000,000 
  
    Net cash provided
    by financing activities 
     6,335,328  
     3,859,608 

    Net increase (decrease) in cash 
     1,264,900  
     (188)
  
    Cash,
    beginning of year 
     1,231  
     1,419 
  
    Cash,
    end of year 
    $1,266,131  
    $1,231 

    Supplemental disclosure
    of Cash Flow Information 

    Cash paid for interest 
     $-  
     $- 
  
    Cash paid for income taxes 
     $-  
     $- 
  
    Supplemental schedule of
    non-cash financing activities: 

    Issuance of warrants on related party line
    of credit 
     $-  
    $5,